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prescribing practices and poor monitoring of therapy
and adherence.
A rational approach is required in which systematic
delivery and proved methods for maximising adher-
ence are as important as procuring the drugs
themselves. This should be led by a respected
international organisation that has the objectives of
overcoming short term suffering as well as preventing
a similar disaster in the long run, by insisting that anti-
retroviral policies incorporate a phase of piloting
systems that seek to maximise adherence.
Contributors and sources: WS has worked with the World Bank
in predicting the effect of HIV in West Africa, and with the
Department for International Development and the London
School of Hygiene and Tropical Medicine on the economics of
tuberculosis control programmes. SK has worked on monitor-
ing HIV drug resistance in trials of antiretroviral therapy
conducted in the United Kingdom and Europe. TC has been in
charge of the clinical services provided by the MRC unit in the
Gambia since 1986 and has specialised in the care and
treatment of patients infected with HIV and tuberculosis.
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Hilary Thomson, Robert Hoskins, Mark Petticrew, David Ogilvie, Neil Craig, Tony Quinn,
Grace Lindsay
Is no evidence better than any evidence when controlled studies are unethical?
Rigorous evidence on the health effects of social inter-
ventions is scarce1 2 despite calls for more evidence
from randomised studies.3 One reason for the lack of
such experimental research on social interventions
may be the perception among researchers, policymak-
ers, and others that randomised designs belong to the
biomedical world and that their application to social
interventions is both unethical and simplistic.4 Apply-
ing experimental designs to social interventions may
be problematic but is not always impossible and is a
desirable alternative to uncontrolled experimenta-
tion.3 However, even when randomised designs have
been used to evaluate social interventions, opportuni-
ties to incorporate health measures have often been
missed.5 For example, income supplementation is
thought to be a key part of reducing health
inequalities,6 but rigorous evidence to support this is
lacking because most randomised controlled trials of
income supplementation have not included health
measures.5 Current moves to increase uptake of
benefits offer new opportunities to establish the
effects of income supplements on health. In
attempting to design such a study, however, we found
that randomised or other controlled trials were
Summary points
Antiretroviral therapy is becoming more
affordable for developing countries
Infrastructure is also essential to deliver the
complex and sensitive drug regimen
DOTS has been suggested as a method for
delivering antiretroviral therapy, although it has
limited success for tuberculosis in much of Africa
Suboptimal adherence to antiretroviral therapy is
likely to result in the transmission of drug
resistant virus strains within the community
Other methods for ensuring adherence need to
be developed and evaluated
Education and debate
MRC Social and
Public Health
Sciences Unit,
Glasgow, G12 8RZ
Hilary Thomson
higher scientific officer
Mark Petticrew
associate director
David Ogilvie
specialist registrar in
public health medicine
Nursing and
Midwifery School,
University of
Glasgow, Glasgow
Robert Hoskins
lecturer
continued over
BMJ 2004;328:282–5
282 BMJ VOLUME 328 31 JANUARY 2004 bmj.com
difficult to justify ethically, and our eventual design
was rejected by funders.
Aims of study
A pilot study carried out by one of us (RH) showed
substantial health gains among elderly people after
receipt of attendance allowance. We therefore decided
to pursue a full scale study of the health effects of
income supplementation. The research team com-
prised a multidisciplinary group of academics and a
representative from the Benefits Agency (TQ). Our
aim was to construct a robust experimental or
quasi-experimental design (in which a control group is
included but not randomly allocated) that would be
sensitive enough to measure the health and social
effects of an attendance allowance award on frail,
elderly recipients.
The intervention
The intervention involved a primary care based
programme that aimed to increase uptake of benefits.
In 2001, community nurses, attached to a general prac-
tice serving the unhealthiest parliamentary constitu-
ency in the United Kingdom,7 screened their frail
elderly clients for unclaimed attendance allowance
(box 1). Potential underclaimants were then visited by a
welfare rights officer, who carried out a benefit assess-
ment, and the claim was then forwarded to the Benefits
Agency (part of the Department of Social Security) for
the final adjudication of applications (figure). This
resulted in 41 clients receiving additional benefit total-
ling £112 892 (€160 307; $200 302), with monthly
incomes increasing by £163-£243.8
Outcomes
We chose change in health status measured by the
SF-36 questionnaire as the main outcome variable.
Explanatory variables, which recipients had linked to
increased income in pilot interviews, were also
incorporated. These included diet, stress levels, levels of
social participation, and access to services.We intended
to assess health status before receipt of the benefit and
at six and 12 months afterwards. An economic evalua-
tion was also planned.
Study design
We initially considered a randomised controlled trial.
However, we encountered problems with the key
elements of this design. The study designs considered
and the issues raised are outlined below.
Design 1: randomisation of the intervention
Under a randomised controlled design successful
claimants would be randomised immediately after the
adjudication decision by the benefits agency. Those in
the control group would have their benefit delayed by
one year, and those in the intervention group would
receive the benefit immediately. This design would
ensure that the health status and benefit eligibility of
both groups were comparable at baseline. However,
the research group considered this design unethical
because of the deliberate withholding of an economic
benefit, which would also be unacceptable to
participants. This design was therefore abandoned.
Design 2: randomising to waiting list
The introduction of a three month waiting list between
initial assessment by a nurse and assessment by the
welfare rights officer provided an opportunity for ran-
dom allocation to the control and intervention group.
We obtained approval to randomise the clients to a
waiting list of a maximum of three months from the
Benefits Agency, which provides the welfare rights
officer. Thus, elderly clients referred by the nurse to the
welfare rights officer could have been randomised to
receive the visit either immediately (the intervention
group) or after three months (the control group).
This design would have allowed us to compare the
groups at the desired time points and provided a
directly comparable control group in terms of health
Community nurses screen
elderly clients (≥65 years)
with possible care needs
Completed claim application sent to
Benefits Agency for final adjudication
Elderly clients
(≥65 years) with no
obvious care needs
Unsuccessful
claimants
Eligible elderly clients referred by
community nurse to welfare rights
officer for in-depth benefit
assessment and processing of claim
Elderly clients judged
by welfare rights
officer as ineligible for
attendance allowance
Successful claimants receive
attendance allowance
Process of screening to promote uptake of attendance allowance.
The groups represented by the boxes on the right would be
unsuitable as controls because they would be systematically different
from benefit recipients in terms of care needs and health status
Box 1 Attendance allowance
• Attendance allowance is payable to people aged 65
or older who need frequent help or supervision and
whose need has existed for at least six months
• The rate payable depends on whether they need
help at home or only when going out and whether
they need help during the day or the evening, or both
Health effects of social intervention can be hard to study
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status and benefit eligibility. However, it randomises
the benefit assessment and not the intervention of
interest (receipt of the benefit), and a delay of three
months would probably not be long enough to detect
important health differences between the two groups.
More importantly, it is unlikely to be ethically
acceptable to request that study participants, already
assessed to be in need of an economic benefit, accept a
50% chance of delaying the application process for
three months in the interests of research. We therefore
rejected this design.
Design 3: non-randomised controlled trial
A third potential design entailed identifying a
non-randomised control group from a nearby area
with a similar sociodemographic composition but with
no welfare rights officers. In this design, community
nurses would have screened potential underclaimants
in the control area, who would then have been offered
a standard leaflet on how to apply for attendance
allowance (a nominal intervention corresponding to
“usual care”). This design would have eliminated some
of the ethical concerns associated with randomisation
and delaying the receipt of benefit, and would have
achieved an intermediate level of internal validity by
retaining a comparison with a control group. However,
recruitment and retention of this control group raises
problems.
The success of this design depends on participants
in the control group delaying their claim for the dura-
tion of the study. Although the effectiveness of the
“usual care” intervention, the leaflet, is normally poor,
we considered it unlikely that this would be the case
after assessment for the study as participants are made
aware of their potential eligibility for the benefit. We
thought it unacceptable to request that participants
delay claiming the additional benefit after drawing
attention to their eligibility.
Design 4: uncontrolled study
A before and after study of a group of benefit
recipients would be more ethically acceptable, but it
would be more difficult to attribute any observed
change in health status to the intervention alone. We
applied for research funding for a study based on this
design, citing the practical and ethical difficulties in
designing a randomised controlled trial, but the appli-
cation was rejected mainly because of the lack of a con-
trol group. We presume that the underlying assump-
tion was that such an uncontrolled study would be so
biased as to provide no useful information.
Discussion
Our initial aimwas to design a randomised or controlled
study to detect the health effects of income supplemen-
tation. Our failure to design such a study and to get
funding for a less rigorous study poses the question of
what sort of evidence is acceptable in such situations.
Social interventions differ from clinical and most
complex public health interventions in that changes in
health are often an indirect effect rather than a primary
aim of the intervention. Investigation of indirect health
effects often requires choices to be made between com-
peting values, usually health and social justice, creating a
moral problem.When, as in our study, the tangible social
and economic gains generated by the social interven-
tions outweigh the theoretical possibility of marginal
health effects, the moral issues are clear.
Randomisation
Although judgments about equipoise have recently
been challenged,9 equipoise around the primary clini-
cal outcome has been the ethical justification for
randomising clinical interventions.10 11 Equipoise
implies uncertainty around the distribution of costs
and benefits between two interventions. Designing a
randomised study may be simple in theory, but in cases
where the equipoise is around uncertain indirect
health impacts, and the primary economic or social
impacts seem certain, true equipoise is unlikely and
randomisation may be unethical.
Randomising a control group need not always
present ethical hurdles. There may be inherent delays in
rolling out a new or reformed programme across an
area, or an interventionmay require rationing or be sub-
ject to long waiting lists. These delays may provide ethi-
cal and pragmatic opportunities for randomisation12;
indeed, randomisation may be the fairest means of
rationing an intervention.13 However, delaying access to
a tangible benefit for individuals who are assessed as “in
need”may not be justifiable on research grounds.
Generating evidence for healthy public policy
An urgent need remains for studies of the indirect
health effects of social interventions to improve our
understanding of the mechanisms by which health
effects can be achieved.14 Attention has already been
drawn to the need for careful design of evaluations of
complex public health interventions,15–17 but guidance
for evaluating the indirect health impacts of social
interventions may require further consideration in
light of the issues outlined above. For example, when
the direct effects are obvious, randomised controlled
trials may be unnecessary and inappropriate.18 In
health technology assessment, other study designs
have an important role in development15 19 and in
helping to detect secondary effects.18 For example, new
drugs with established pharmacological mechanisms
Summary points
The health effects of social interventions have
rarely been assessed and are poorly understood
Studies are required to identify the possible
positive or negative health impacts and the
mechanisms for these health impacts
The assessment of indirect health effects of social
interventions draws attention to competing values
of health and social justice
Randomisation of a social intervention may be
possible using natural delays, but adding delays
for the sole purpose of health research is often
unethical
When randomised or other controlled studies are
not ethically possible, uncontrolled studies may
have to be regarded as good enough
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are investigated at increasing levels of internal and
external validity before being tested in a population
level randomised controlled trial. Phase I and II studies
are often small and uncontrolled, but they help to
establish positive and negative effects, clarify the dose-
response relations, and provide the background for
larger trials.15 19 In addition, once approved, drugs are
closely monitored at a population level to detect previ-
ously unidentified secondary adverse effects that may
outweigh the primary positive effects.18 Our pilot study
was similar to a phase II study.
This matching of study designs to the level of
development and knowledge of the effects of an inter-
vention could be usefully applied to the study of social
interventions. Non-randomised and uncontrolled
studies could be used to shed light on the nature and
possible size of health effects in practice, to illustrate
mechanisms, and to establish plausible outcomes.18
Such studies may serve as a precursor to experimental
studies when these are ethically justifiable and
appropriate. However, when randomised studies are
not possible, we may have to accept data from uncon-
trolled studies as good enough, given the huge gaps in
our knowledge.14 We need to reconsider what sort of
evidence is required, how this should be assembled and
for what purpose, and the trade offs between bias and
utility so that study designs that are acceptable to
research participants, users, and funders can be agreed.
We thank Sally Macintyre and Graham Hart for comments on a
previous draft of this article.
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Two memorable patients
Two nil
It is a dull wet Saturday afternoon in Goodison Park. The fans are
filing in, and there is a tense excited atmosphere around the
ground. It is nearing the end of the season, and everyone is
hoping the seemingly inevitable relegation battle can be avoided
this year. The Goodison faithful are buzzing with the prospect of
taking three points from fellow strugglers. Behind the scenes, the
usual band of St John Ambulance volunteers have
gathered—doctors, nurses, firemen, policemen, dockers, students,
and others from all walks of life.
As the match enters the last five minutes, the only thought
echoing around the ground is how to put the ball into the goal.
Until, that is, a simple radio message is received: “Code Blue,
cardiac arrest in the Lower Bullens stand.”
Our team jumps into action. We arrive to find an unresponsive,
cyanotic, elderly man stretched out across four seats.
Cardiopulmonary resuscitation is already being performed by a
dockworker; he’s an experienced first aider. Other members of
our team and the club doctor arrive with oxygen and an
automatic defibrillator. The casualty is in ventricular fibrillation,
and the first three shocks are given immediately, but with no
effect. We intubate and cannulate him, as slick as any hospital
arrest team. A fourth shock is given, and we get a result—the
rhythm change that everyone is looking for. A spontaneous
circulation is returned.
Just as we all relax, lightning strikes twice: “Code Blue, cardiac
arrest in the Gwladys Street stand.” Half our team go tearing off
to the second incident, with the match now in injury time. A
second unresponsive man is found in cardiac arrest, but not for
long. We are joined by an ambulance service team and soon once
more have a spontaneous output.
The crowd are now filing out, blissfully unaware as two
paramedic vehicles arrive. The first man has spat out his
endotracheal tube and is conscious, asking what the score is. Two
live casualties are taken to hospital. Our team of volunteers
returns to the first aid point buzzing, but football and relegation
are no longer important. The only score on everyone’s mind now
is St John 2—Undertakers 0.
Working in a state of the art hospital surrounded by machines
that go beep and staff who have trained in their professions for
many years can sometimes make us forget the basics. It is
humbling to remember that the two lives saved that day weren’t
due to fancy new techniques or expensive modern technology.
They were saved by a group of volunteers, the likes of whom may
be found at every major sporting event and public gathering
across the country.
Joanne Banks orthopaedic specialist registrar,Mersey Deanery
Rotation
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